Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer

Kobayashi-Kato, Mayumi; Yunokawa, Mayu; Bun, Seiko; Matsuda, Naoyuki; Kato, Tomoyasu; Tamura, Kenji

doi:10.1007/s00280-019-03834-1

Cited by 9 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings might have important implications for the future management of patients on PLD therapy. First, we found that a previous response status to firstline platinum-based chemotherapy was a predictive factor of the objective response, which is in line with previous studies [19][20][21].…”

Section: Discussionsupporting

confidence: 91%

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

et al. 2021

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clinical trial. The ORR was the interim primary objective, and the DCR, AEs and QOL were the secondary objectives. The impact of factors on efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints. Results Totally, 115 patients were enrolled in this study and included in the ITT population. Moreover, 101 patients were included in the safety population. The median follow-up time was 4 months (IQR 2–6). In the ITT population, the confirmed ORR was 37.4% (95% CI, 28.4–46.4%), and the DCR was 65.2% (95% CI, 56.4–74.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were significantly correlated with the ORR. The ORR was significantly higher in patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires. Conclusions For patients who experience platinum-resistant and platinum-refractory relapse, the use of PLD may be acceptable because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a low CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for satisfactory efficacy.

show abstract

Section: Discussionsupporting

confidence: 91%

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…First, we found that a previous response status to rst-line platinum-based chemotherapy was a predictive factor of the objective response, which is in line with previous studies [19][20][21].…”

Section: Discussionsupporting

confidence: 91%

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Yuan

Zhang

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Objective To evaluate the efficacy and safety of PLD in treating of in patients with epithelial ovarian, tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clinical trial. ORR was the interim primary objective and DCR, AEs and QOL were the secondary objectives. The impact of factors on the efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints. Results Totally, 115 patients were enrolled in this study and included in the ITT. Moreover, 101 patients were included in the safety analysis. The median follow-up time was 4 months (IQR 2–6). In ITT, the confirmed ORR was 37.4% (95%CI, 28.4%-46.4%), and the DCR was 65.2% (95%CI, 56.4%-74.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were statistically correlated with the ORR. The ORR was significantly higher in the patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires. Conclusions For patients with platinum-resistant and platinum refractory relapse, the use of PLD may be a favorite choice because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a lower CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for a better efficacy.

show abstract

“…The preliminary clinical activity observed, even in this low number of patients, is encouraging. Patient subgroups with multiple poor prognostic factors including 3 prior lines of therapy [17] as well as short PFIs of <3 months [18] showed encouraging response to treatment. Although clinical activity was higher in the paclitaxel cohort regardless of dose, those with AVB-500 C1D15 trough levels greater than 13.8 mg/L tended to show better clinical activity.…”

Section: Discussionmentioning

confidence: 96%

“…Patients with the historically poor prognostic indicators of advanced lines of chemotherapy, defined as two prior lines of chemotherapy [17], or PFI < 3 months [18] showed beneficial activity (Table S4). The ORR in patients treated with 2 to 3 prior lines of therapy was 8/29 (28%, 95% CI: 12.7%, 47.2%) including 2 CRs (Table S4 A).…”

Section: Subgroup Analysesmentioning

confidence: 99%

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Fuh

Bookman

Liu

et al. 2021

Gynecologic Oncology

View full text Add to dashboard Cite

The combination of AVB-500 plus chemotherapy was safe and tolerable with no DLTs identified.• At the AVB-500 RP2D (15 mg/kg), AVB-500+PAC demonstrated better clinical activity than AVB-500+PLD.• Patients with no prior bevacizumab had greater clinical response than those with prior bevacizumab and historical control.• An exposure-response relationship was identified for AVB-500 trough levels >13.8 mg/L exhibiting greater clinical response.• A pretreatment serum biomarker may identify patients who benefit from AVB-500 in combination with chemotherapy.

show abstract

Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer

Cited by 9 publications

References 18 publications

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Contact Info

Product

Resources

About